Now, blood flow distributes active drugs throughout the brain with off-target  effects limiting on-target doses to suboptimal levels. Our two-part solution is patent-protected: a) engineer nanocarriers to deliver and selectively release drugs in zones of high brain activity and b) increase activity in these target zones using proprietary digital perceptual/cognitive stimulation technology. Chemical conditions related to localized increase in neuronal firing trigger carrier/drug decoupling. With Blavatnik funds we would engineer 2-Deoxyglucose-drug conjugates for targeted release of anti-depressant and Alzheimer's drugs. We have a world-class team, NewCo and CEO for scaling and commercialization. The 2-Deoxyglucose-drug conjugates would be Yale IP.